Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Debt to Equity (2018 - 2022)

Historic Debt to Equity for Theravance Biopharma (TBPH) over the last 5 years, with Q2 2022 value amounting to -$1.13.

  • Theravance Biopharma's Debt to Equity rose 1095.92% to -$1.13 in Q2 2022 from the same period last year, while for Jun 2022 it was -$1.13, marking a year-over-year increase of 1095.92%. This contributed to the annual value of -$1.15 for FY2021, which is 1117.89% up from last year.
  • As of Q2 2022, Theravance Biopharma's Debt to Equity stood at -$1.13, which was up 1095.92% from -$1.12 recorded in Q1 2022.
  • In the past 5 years, Theravance Biopharma's Debt to Equity registered a high of -$1.02 during Q4 2019, and its lowest value of -$4.45 during Q4 2018.
  • For the 5-year period, Theravance Biopharma's Debt to Equity averaged around -$1.62, with its median value being -$1.27 (2021).
  • Its Debt to Equity has fluctuated over the past 5 years, first soared by 7699.13% in 2019, then crashed by 2612.86% in 2020.
  • Theravance Biopharma's Debt to Equity (Quarter) stood at -$4.45 in 2018, then soared by 76.99% to -$1.02 in 2019, then fell by 26.13% to -$1.29 in 2020, then grew by 11.18% to -$1.15 in 2021, then increased by 1.26% to -$1.13 in 2022.
  • Its Debt to Equity was -$1.13 in Q2 2022, compared to -$1.12 in Q1 2022 and -$1.15 in Q4 2021.